|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | A new communication system between hepatocytes and sinusoidal endothelial cells in liver through vascular endothelial growth factor and Fittyrosine kinase receptor family ( Fit- 1 and KDR/Flk- 1 ) 显示文摘 | Yamane A Seetharam L Yamaguchi S etal | 1994 | Oncogene1994，9，： | 1 |
| 2 | A unique signal transduction from FLT tyrosine,a receptor for vascular endothelial growth factor VEGF显示文摘 | Seetharam L Gotoh N Maru Y | 1995 | Oncogene1995，10，： | 1 |
| 3 | A unique signal transduction from FLT tyrosine kinase,a receptor for vascular endothelial growth factor(VEGF)显示文摘 | Seetharam L Gotoh N Maru Y | 1995 | Oncogene1995，10，： | 1 |
| 4 | Clinical characterizationof acute leukemia with myelodysplasia-related changes as defined bythe 2008 WHO classification system显示文摘 | Weinberg O K Seetharam M Ren L | 2009 | Blood2009，113，9： | 1 |
| 5 | Cholesterol binding, efflux,and a PDZ- interacting domain of scavenger receptor- BI mediate HDL- initiated signaling显示文摘 | Assanasen C Mineo C Seetharam D et a l | 2005 | J Clin Invest2005，115，4： | 1 |
| 6 | A new communication system between hepatocytes and sinusoidal endothelial cells in liver through vascular endothelial growth factor and Flt tyrosine kinase receptor family (Flt-1 and KDR/Flk-1)显示文摘 | Yamane A Seetharam L Yamaguchi S | 1994 | Oncogene1994，9，9： | 1 |
| 7 | A unique signal transductoin from VEGF显示文摘 | Seetharam L | 1995 | Oncogene1995，10，： | 1 |
| 8 | A unique signal transduction from FLT tyrosine kinase,a receptor for vascular endothelial growth factor VEGF显示文摘 | SEETHARAM L GOTOH N MARU Y | 1995 | Oncogene1995，10，1： | 1 |
| 9 | A unique signal transduction from FLT tyrosine kinase,a receptor for vascular endothelial growth factor (VEGF) 显示文摘 | Seetharam L Goton N Maru Y | 1995 | Oncogene1995，10，： | 1 |
| 10 | Clinical cha?racterization of acute myeloid leukemia with myelodyspla?sia-related changes as defined by the 2008 WHO classi?fication system显示文摘 | Weinberg OK Seetharam M Ren L | 2009 | Blood2009，113，9： | 1 |
| 11 | A unique signaltransduction form FLT lyrosine kinase,a receptor for vascular endothelial growth factor VEGF显示文摘 | Seetharam L Gotoh N Maru Y | 1995 | Oncogene1995，10，1： | 1 |
| 12 | A new communica- tion system between hepatocytes and sinusoidal endothelial cells in liver through vascular endothelial growth factor and Fit tyrosine kinase receptor family(Fit-I and KDR/Flk-I)显示文摘 | Yamane A Seetharam L Yamaguchi S | 1994 | Oncogene1994，9，9： | 1 |
| 13 | Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system显示文摘 | Weinberg OK Seetharam M Ren L | 2009 | Blood2009，113，： | 1 |
| 14 | A unique signal transduction from FLT tyrosine kinase,a receptor for vascular endothelial growth factor(VEGF)显示文摘 | Seetharam L Gotoh N Maru Y | 1995 | Oncogene1995，10，1： | 1 |
| 15 | A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor(VEGF)显示文摘 | Gotoh N Maru Y | 1995 | Oncogene1995，10，1： | 1 |
| 16 | A new communication system between hepatocytes and sinusoidal endothelial cells in liver through vascular endothelial growth factor and Fhtyrosine kinase receptor family (Fh-1 and KDR/Flk-1) 显示文摘 | Yamane A Seetharam L Yamaguchi S | 1994 | Oncogene1994，9，9： | 1 |
| 17 | Oncologic outcomes with and without amniotic membranes in robotic-assisted radical prostatectomy:A propensity score matched analysis显示文摘Objective:Placement of human placenta derived grafts during robotic-assisted radical prostatectomy(RARP)hastens the return of continence and potency.The long-term impact on the oncologic outcomes remains to be investigated.Our objective was to determine the oncologic outcomes of patients with dehydrated human amnion chorion membrane(dHACM)at RARP compared to a matched cohort.Methods:In a referral centre,from August 2013 to October 2019,599 patients used dHACM in bilateral nerve-sparing RARP.We excluded patients with less than 12 months follow-up,simple prostatectomy,and unilateral nerve-sparing.Patients with dHACM(amnio group)were 529,and were propensity score matched 1:1 to 2465 patients without dHACM(non-amnio group)and a minimum follow-up of 36 months.At the time of RARP,dHACM was placed around the neurovascular bundle in the amnio group.Continuous and categorical variables in matched groups was tested by two-sample Kolmogorov-Smirnov test and Fisher's exact test respectively.Outcomes measured were biochemical recurrence(BCR),adjuvant and salvage therapy rates.Results:Propensity score matching resulted in two groups of 444 patients.Cumulative incidence functions for BCR did not show a difference between the groups(p=0.3).Patients in the non-amnio group required salvage therapy more frequently than the amnio group,particularly after partial nerve-sparing RARP(6.3%vs.2.3%,p=0.001).Limitations are the absence of prospective randomization.Conclusion:The data suggest that using dHACM does not have a negative impact on BCR in patients.Outcomes of cancer specific and overall survival will require follow-up study to increase our understanding of these grafts’impact on prostate cancer biology. | Jonathan Noël Daniel Stirt Marcio Covas Moschovas Sunil Reddy Abdel Rahman Jaber Marco Sandri Seetharam Bhat Travis Rogers Subuhee Ahmed Anya Mascarenhas Ela Patel Vipul Patel | 2024 | Asian Journal of Urology2024，11，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员